Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

FOLD

Amicus Therapeutics Inc

Dec 19 • 04:00PM ET

14.18

+3.29 30.21 %

Healthcare • Biotechnology • USA • NASD

Dec 19, 7:50 AMBioMarin to acquire Amicus Therapeutics for $4.8 billion in an all-cash definitive deal at $14.50 per share (33% premium), unanimously approved by both boards with closing targeted for Q2 2026 pending approvals.

Peers: VRTX SRPT BMRN REGN CRSP EDIT PFE QURE AGIO BLUE

| Held by: VTI IWM VB XBI VBK VXF IWO IBB SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.04	Insider Own	2.08%	Shs Outstand	308.50M	Perf Week	34.41%
Market Cap	4.38B	Forward P/E	52.80	EPS next Y	0.27	Insider Trans	-5.25%	Shs Float	302.11M	Perf Month	45.73%
Enterprise Value	4.55B	PEG	-	EPS next Q	0.07	Inst Own	103.15%	Short Float	6.39%	Perf Quarter	65.46%
Income	-14.06M	P/S	7.31	EPS this Y	89.68%	Inst Trans	-0.84%	Short Ratio	3.57	Perf Half Y	148.34%
Sales	598.70M	P/B	18.98	EPS next Y	1546.18%	ROA	-1.70%	Short Interest	19.31M	Perf YTD	50.53%
Book/sh	0.75	P/C	16.58	EPS next 5Y	-	ROE	-6.87%	52W High	11.14 27.29%	Perf Year	43.38%
Cash/sh	0.86	P/FCF	451.50	EPS past 3/5Y	41.55% 34.10%	ROIC	-2.12%	52W Low	5.51 157.35%	Perf 3Y	13.90%
Dividend Est.	-	EV/EBITDA	108.12	Sales past 3/5Y	20.03% 23.72%	Gross Margin	88.50%	Volatility	3.21% 3.89%	Perf 5Y	-40.62%
Dividend TTM	-	EV/Sales	7.61	EPS Y/Y TTM	87.30%	Oper. Margin	5.77%	ATR (14)	0.61	Perf 10Y	50.69%
Dividend Ex-Date	-	Quick Ratio	2.09	Sales Y/Y TTM	21.28%	Profit Margin	-2.35%	RSI (14)	91.12	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	2.99	EPS Q/Q	352.49%	SMA20	37.52%	Beta	0.44	Target Price	16.93
Payout	-	Debt/Eq	1.92	Sales Q/Q	19.46%	SMA50	50.19%	Rel Volume	34.61	Prev Close	10.89
Employees	499	LT Debt/Eq	1.88	Earnings	Nov 04 BMO	SMA200	84.87%	Avg Volume	5.41M	Price	14.18
IPO	May 31, 2007	Option/Short	Yes / Yes	EPS/Sales Surpr.	55.44% 2.02%	Trades		Volume	187,195,039	Change	30.21%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-17-25	Initiated	Citigroup	Buy	$17
Sep-18-25	Upgrade	Needham	Hold → Buy	$14
Jul-17-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$108
Dec-13-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$17 → $12
Sep-06-24	Initiated	Jefferies	Buy	$18
May-30-24	Initiated	Wells Fargo	Overweight	$18
May-14-24	Upgrade	Guggenheim	Neutral → Buy	$13
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$15 → $20
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight	$14
Apr-13-22	Resumed	Goldman	Neutral	$11
Jan-14-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$12 → $16
Nov-15-21	Upgrade	Stifel	Hold → Buy	$12 → $16
Sep-30-21	Upgrade	JP Morgan	Neutral → Overweight	$16
Jul-19-21	Resumed	BTIG Research	Buy	$15
May-27-21	Initiated	Needham	Hold
May-21-21	Initiated	UBS	Buy	$16
Apr-14-21	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$17
Mar-02-21	Initiated	Stifel	Hold	$13
Feb-12-21	Downgrade	JP Morgan	Overweight → Neutral	$19
Feb-12-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$30 → $17

Show Previous Ratings

Today 04:32PM	Stocks to Watch Friday Recap: Lamb Weston, Intuitive Machines, Nike, Oracle (The Wall Street Journal) +30.21%
04:17PM	BioMarin Soars 18% After Folding In The $4.8 Billion Takeover Of Amicus (Investor's Business Daily)
10:55AM	BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping. (Barrons.com)
12:41PM	Biotech Bombshell: BioMarin's $4.8B Bet Ignites Amicus Shares in Rare-Disease Power Play (GuruFocus.com)
12:17PM	Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates (Zacks)
11:57AM	Loading…
11:57AM	BioMarin to Buy Rare-Disease Biotech Amicus Therapeutics for $4.8 Billion (The Wall Street Journal)
11:01AM	Stocks to Watch Friday: Lamb Weston, Intuitive Machines, Nike, Oracle (The Wall Street Journal)
09:38AM	Stocks to Watch Friday: Nike, Oracle, FedEx, Sony (The Wall Street Journal)
09:33AM	BioMarin Pharmaceutical Scoops Up Amicus Therapeutics In $4.8 Billion Deal (Investor's Business Daily)
08:13AM	BioMarin to Buy Amicus Therapeutics for $4.8 Billion (The Wall Street Journal)
07:45AM	BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook (PR Newswire)
Dec-18-25 03:43AM	Zacks Industry Outlook Arcutis, Amicus and ANI (Zacks)
Dec-17-25 02:19PM	5 Biotech Stocks to Watch for Potential Upside (Zacks)
Dec-16-25 10:30AM	FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock? (Zacks)
08:53AM	GILD's Bictegravir and Lenacapavir Regimen for HIV Meets Primary Goal (Zacks)
09:59AM	Loading…
Dec-15-25 09:59AM	RCUS Stock Down on Decision to Discontinue GILD Partnered Study (Zacks)
Dec-13-25 07:05AM	Amicus Therapeutics (FOLD) Soars to 52-Week High on 'Strong Buy' Reco (Insider Monkey)
Dec-12-25 09:55AM	Wall Street Analysts See a 60.61% Upside in Amicus Therapeutics (FOLD): Can the Stock Really Move This High? (Zacks) +6.57%
Dec-09-25 01:48PM	The Best Cheap Stocks Under $10 to Buy in December and 2026 (Zacks)
Dec-08-25 08:23AM	Beat the Market the Zacks Way: Veracyte, Las Vegas Sands, 3M in Focus (Zacks)
Dec-05-25 12:20PM	Surging Earnings Estimates Signal Upside for Amicus Therapeutics (FOLD) Stock (Zacks)
09:57AM	Can Galafold Continue to Drive Amicus' Top Line in 2026? (Zacks)
Dec-04-25 11:30AM	Amicus Therapeutics (FOLD) Up 6.4% Since Last Earnings Report: Can It Continue? (Zacks)
10:29AM	BMY Gains on News of Continuation of Alzheimer's Disease Study (Zacks)
Dec-02-25 02:20PM	BHC Stock Up as Solta Acquires Shibo's Aesthetics Distribution Business (Zacks)
Nov-26-25 09:55AM	Wall Street Analysts Think Amicus Therapeutics (FOLD) Could Surge 58.46%: Read This Before Placing a Bet (Zacks)
Nov-25-25 02:00PM	FDA Greenlights Novartis' Gene Replacement Treatment for SMA (Zacks)
Nov-24-25 01:53PM	BAYRYs Cardiovascular Drug Hits Goals in Late-Stage Study (Zacks)
Nov-21-25 10:15AM	NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth (Zacks)
Nov-19-25 08:53AM	BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU (Zacks)
08:11AM	Loading…
Nov-14-25 08:11AM	GILD's Investigational Regimen for HIV Treatment Meets Primary Goal (Zacks)
Nov-13-25 01:46PM	Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth? (Zacks)
Nov-11-25 12:52PM	Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus (Zacks)
Nov-10-25 08:16PM	Goldman Sachs Bullish on Amicus Therapeutics (FOLD) Following Q3 2025 Results (Insider Monkey)
09:55AM	Wall Street Analysts Believe Amicus Therapeutics (FOLD) Could Rally 76.32%: Here's is How to Trade (Zacks)
01:44AM	Zacks.com featured highlights include EverQuote, Amicus, Lam Research and Cboe Global Markets EverQuote, Amicus, Lam Research and Cboe Global Markets (Zacks)
Nov-07-25 10:40AM	Bet on These 4 Top-Performing Liquid Stocks to Maximize Returns (Zacks)
Nov-06-25 10:43AM	Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
10:24AM	Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance (Zacks)
09:24AM	RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y (Zacks)
08:27AM	ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales (Zacks)
Nov-05-25 10:52AM	EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales (Zacks)
10:48AM	Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y (Zacks)
10:41AM	Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up (Zacks)
10:30AM	Novo Nordisk Q3 Earnings & Revenues Miss, GLP-1 Drugs Face US Hurdles (Zacks)
10:08AM	Amicus' Q3 Earnings Beat, Higher Product Sales Drive Y/Y Revenues (Zacks)
09:30AM	Compared to Estimates, Amicus Therapeutics (FOLD) Q3 Earnings: A Look at Key Metrics (Zacks)
Nov-04-25 04:07PM	Amicus Therapeutics Inc (FOLD) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
11:43AM	ZTS Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down (Zacks)
09:54AM	Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
08:35AM	Amicus Therapeutics (FOLD) Beats Q3 Earnings and Revenue Estimates (Zacks)
07:29AM	Amicus Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
Oct-31-25 01:45PM	Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates (Zacks)
10:37AM	ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales (Zacks)
07:00AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025 (GlobeNewswire)
Oct-30-25 10:28AM	BHC Stock Up on Q3 Earnings Beat, Salix and Solta Drive Sales (Zacks)
Oct-23-25 07:00AM	Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025 (GlobeNewswire)
Oct-14-25 08:23AM	FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months (Zacks)
Oct-08-25 11:23AM	Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease (Zacks)
12:57AM	What Does Wall Street Think About Amicus Therapeutics (FOLD)? (Insider Monkey)
Oct-07-25 12:00PM	All You Need to Know About Amicus Therapeutics (FOLD) Rating Upgrade to Strong Buy (Zacks)
11:32AM	SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II Goal (Zacks)
08:34AM	Zacks.com featured highlights include Amicus Therapeutics, Micron Technology and General Dynamics (Zacks)
Oct-06-25 09:22AM	Bet on These 3 Stocks With Upgraded Broker Ratings for Solid Returns (Zacks)
Oct-02-25 09:40AM	Can Galafold Drive Amicus' Growth Through the Rest of 2025? (Zacks) +7.00%
Sep-25-25 11:26AM	RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential? (Zacks)
09:28AM	Atara Biotherapeutics (ATRA) Soars 10.0%: Is Further Upside Left in the Stock? (Zacks)
Sep-19-25 09:31AM	Strength Seen in Amicus Therapeutics (FOLD): Can Its 6.4% Jump Turn into More Strength? (Zacks)
Sep-18-25 09:38AM	Target initiated, Nike upgraded: Wall Street's top analyst calls (The Fly) +6.40%
Sep-08-25 09:00AM	New 4-Year Data for Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) Presented at ICIEM (GlobeNewswire)
Aug-29-25 07:00AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025 (GlobeNewswire)
05:08AM	Amicus Therapeutics, Inc. (FOLD) Expands Pipeline With Rare Kidney Disease Drug (Insider Monkey)
Aug-06-25 08:30AM	Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators (PR Newswire)
Aug-05-25 12:20PM	Earnings Estimates Moving Higher for Amicus Therapeutics (FOLD): Time to Buy? (Zacks)
09:55AM	Does Amicus Therapeutics (FOLD) Have the Potential to Rally 138.21% as Wall Street Analysts Expect? (Zacks)
Aug-03-25 05:00PM	Amicus Therapeutics Inc (FOLD) Q2 2025 Earnings Call Highlights: Sustained Revenue Growth ... (GuruFocus.com)
Aug-01-25 11:49AM	FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales (Zacks) +5.51%
Jul-31-25 08:15AM	Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates (Zacks)
07:11AM	Amicus Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
Jul-25-25 10:00AM	Moderna (MRNA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-24-25 11:47PM	Morgan Stanley Upgrades Amicus (FOLD) on IP Strength and Pipeline Expansion (Insider Monkey)
10:00AM	Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-21-25 07:00AM	Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025 (GlobeNewswire)
Jul-18-25 06:57AM	Fabry Disease Treatment Analysis Report 2025 \| Market to Reach $3.86 Billion by 2030, Rising Fabry Disease Prevalence and Demand for Targeted Therapies Drive Growth (GlobeNewswire) -5.25%
Jul-17-25 09:46AM	Starbucks downgraded, Oracle initiated: Wall Street's top analyst calls (The Fly)
Jul-16-25 12:23PM	Amicus (FOLD) Gets Japan Approval for Pombiliti + Opfolda (Insider Monkey)
Jul-11-25 11:27AM	TD Cowen Remains Bullish on Amicus Therapeutics (FOLD) With a $20 PT (Insider Monkey)
Jul-06-25 04:15AM	Amicus Therapeutics (FOLD) Announces Approval for Pombiliti + Opfolda by Japan's Ministry of Health, Labour and Welfare (MHLW) (Insider Monkey)
Jun-25-25 07:00AM	Amicus Therapeutics Announces Approval of Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) in Japan (GlobeNewswire)
Jun-24-25 12:45PM	Amicus Therapeutics Publishes Positive PROPEL Study Data for Pompe Disease Treatment (Insider Monkey)
Jun-03-25 07:45AM	New Strong Sell Stocks for June 3rd (Zacks)
07:00AM	New Analysis of Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) Published in Muscle and Nerve (GlobeNewswire)
May-30-25 07:00AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 (GlobeNewswire)
May-13-25 08:51AM	Is Amicus Therapeutics (FOLD) the Best Low Priced Biotech Stock to Buy Now? (Insider Monkey)
May-07-25 07:00AM	Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference (GlobeNewswire)
May-02-25 01:18PM	FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls (Zacks)
May-01-25 04:24PM	Amicus Therapeutics, Inc. (FOLD) Q1 2025 Earnings Call Transcript (Seeking Alpha) -13.02%
10:44AM	Dimerix and Amicus to commercialise DMX-200 in US (Pharmaceutical Technology)

Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DAVID CLARK	Officer	Dec 19 '25	Proposed Sale	10.89	25,642	279,241		Dec 19 04:22 PM
Campbell Bradley L	President and CEO	Dec 15 '25	Option Exercise	9.03	70,426	635,947	1,207,708	Dec 17 06:21 PM
Campbell Bradley L	President and CEO	Dec 15 '25	Sale	10.86	77,926	846,011	1,129,782	Dec 17 06:21 PM
Clark David Michael	Chief People Officer	Dec 15 '25	Sale	11.00	25,643	282,073	271,332	Dec 17 06:19 PM
BRADLEY CAMPBELL	Director	Dec 15 '25	Proposed Sale	10.55	77,926	822,119		Dec 15 04:32 PM
DAVID CLARK	Officer	Dec 15 '25	Proposed Sale	10.55	25,643	270,534		Dec 15 04:17 PM
Campbell Bradley L	President and CEO	Dec 01 '25	Option Exercise	9.03	14,587	131,721	1,151,869	Dec 03 08:11 PM
Campbell Bradley L	President and CEO	Dec 01 '25	Sale	10.01	14,587	146,011	1,137,282	Dec 03 08:11 PM
BRADLEY CAMPBELL	Director	Dec 01 '25	Proposed Sale	9.93	14,587	144,849		Dec 01 04:19 PM
Castelli Jeff	Chief Development Officer	Nov 24 '25	Option Exercise	9.03	50,000	451,500	515,476	Nov 26 09:18 PM
Castelli Jeff	Chief Development Officer	Nov 24 '25	Sale	10.16	76,158	773,659	439,318	Nov 26 09:18 PM
Clark David Michael	Chief People Officer	Nov 24 '25	Sale	10.10	25,643	258,933	296,975	Nov 26 09:17 PM
Campbell Bradley L	President and CEO	Nov 24 '25	Option Exercise	9.03	14,587	131,721	1,151,869	Nov 26 09:17 PM
Campbell Bradley L	President and CEO	Nov 24 '25	Sale	10.04	14,587	146,522	1,137,282	Nov 26 09:17 PM
Rosenberg Ellen	Chief Legal Officer	Nov 24 '25	Option Exercise	5.80	36,000	208,930	543,710	Nov 26 09:16 PM
Rosenberg Ellen	Chief Legal Officer	Nov 25 '25	Option Exercise	5.13	36,000	184,680	543,710	Nov 26 09:16 PM
Rosenberg Ellen	Chief Legal Officer	Nov 26 '25	Option Exercise	5.13	23,621	121,176	531,331	Nov 26 09:16 PM
Rosenberg Ellen	Chief Legal Officer	Nov 24 '25	Sale	10.06	36,000	362,268	507,710	Nov 26 09:16 PM
Rosenberg Ellen	Chief Legal Officer	Nov 25 '25	Sale	10.00	36,000	360,000	507,710	Nov 26 09:16 PM
Rosenberg Ellen	Chief Legal Officer	Nov 26 '25	Sale	10.00	23,621	236,210	507,710	Nov 26 09:16 PM
ELLEN ROSENBERG	Officer	Nov 26 '25	Proposed Sale	9.87	23,621	233,139		Nov 26 04:18 PM
ELLEN ROSENBERG	Officer	Nov 25 '25	Proposed Sale	9.89	36,000	356,040		Nov 25 04:27 PM
JEFFREY CASTELLI	Officer	Nov 24 '25	Proposed Sale	9.56	76,158	728,070		Nov 24 04:25 PM
DAVID CLARK	Officer	Nov 24 '25	Proposed Sale	9.56	25,643	245,147		Nov 24 04:24 PM
BRADLEY CAMPBELL	Director	Nov 24 '25	Proposed Sale	9.56	14,587	139,452		Nov 24 04:24 PM
ELLEN ROSENBERG	Officer	Nov 24 '25	Proposed Sale	9.56	36,000	344,160		Nov 24 04:23 PM
Clark David Michael	Chief People Officer	Nov 04 '25	Sale	9.51	25,643	243,860	322,618	Nov 05 04:05 PM
DAVID CLARK	Officer	Nov 04 '25	Proposed Sale	8.86	25,643	227,197		Nov 04 04:33 PM
Campbell Bradley L	President and CEO	Feb 19 '25	Option Exercise	9.03	400	3,612	1,151,057	Feb 21 07:27 PM
Campbell Bradley L	President and CEO	Feb 19 '25	Sale	10.00	400	4,000	1,150,657	Feb 21 07:27 PM
BRADLEY CAMPBELL	Director	Feb 19 '25	Proposed Sale	9.85	400	3,940		Feb 19 04:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FOLD

Amicus Therapeutics Inc

Upgrade your FINVIZ experience